Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria
Venous thromboembolism is the most common cause of death in cancer patients with venous thrombosis. Treatment of venous thrombosis is important in cancer patients, as it can have a major impact on prognosis. We report a case of advanced gastric cancer that was discovered owing to pulmonary thromboem...
Main Authors: | Takuro Takama, Mitsunori Fukue, Koji Kanaya, Masato Taniuchi |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-09-01
|
Series: | SAGE Open Medical Case Reports |
Online Access: | https://doi.org/10.1177/2050313X19878047 |
Similar Items
-
Edoxaban for the Long‐Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?
by: Giuseppe Camporese, et al.
Published: (2021-01-01) -
Edoxaban in venous thromboembolism and stroke prevention: an appraisal
by: Proietti M, et al.
Published: (2016-02-01) -
Risk impact of edoxaban in the management of stroke and venous thromboembolism
by: Hurst KV, et al.
Published: (2016-08-01) -
Edoxaban for prevention of venous thromboembolism after major orthopedic surgery
by: Kawaji H, et al.
Published: (2012-05-01) -
Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism
by: Tellor KB, et al.
Published: (2016-04-01)